NCT02232620

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Sumitomo Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy due to disease progression, adverse events, or another discontinuation criterion. Safety, tolerability and efficacy of BBI503 will be assessed for the duration of study treatment.

Conditions

• Gastrointestinal Stromal Tumors

Interventions

Type	Name	Description
DRUG	BBI503	BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.

Timeline

• Start date: 2017-03-13
• Primary completion: 2017-07-25
• Completion: 2017-07-25
• First posted: 2014-09-05
• Last updated: 2023-11-14

Locations

1 site across 1 country: Canada